Physician
LR Medical PLLC
LR Medical PLLC was paid $1.98M by Medicaid between Jan 2018 and Nov 2024, across 40 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 76% of everything it billed.
33Billing provider infoLR MEDICAL PLLC
BROOKLYN, NY 11223
BROOKLYN, NY 11223
33aNPI1760808802assigned 03/13/2014
33bProvider typePain Medicine (Physical Medicine & Rehabilitation) Physician
28Total paid$1.98M
24GClaims54,248
24DCodes billed40
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in New York
Rank by total paid#3 of 104
Median peer was paid$17K
This provider vs. median117×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,156 | $372K | |
| 2019 | 12,641 | $261K | |
| 2020 | 5,564 | $244K | |
| 2021 | 4,960 | $274K | |
| 2022 | 4,458 | $277K | |
| 2023 | 5,492 | $317K | |
| 2024incomplete | 3,977 | $238K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 76% | 25,129 | 22,964 | $1.50M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 8.4% | 1,904 | 1,900 | $167K |
| 62323 | 3.2% | 765 | 751 | $63K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 546 | 526 | $46K |
| 20610 | <1% | 329 | 297 | $14K | |
| 95886 | <1% | 95 | 94 | $11K | |
| 83992 | <1% | 1,285 | 1,275 | $10K | |
| 95911 | <1% | 72 | 71 | $10K | |
| 80360 | <1% | 1,245 | 1,235 | $10K | |
| 80305 | <1% | 1,448 | 1,438 | $9K | |
| 80371 | <1% | 1,164 | 1,154 | $9K | |
| 80354 | <1% | 1,165 | 1,155 | $9K |
28 more codes
| 80357 | <1% | 1,165 | $9K | |
| 80368 | <1% | 1,150 | $9K | |
| 80372 | <1% | 1,150 | $8K | |
| 80373 | <1% | 1,150 | $8K | |
| 80370 | <1% | 1,156 | $8K | |
| 80346 | <1% | 1,246 | $8K | |
| 80324 | <1% | 1,285 | $8K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 42 | $7K |
| 80356 | <1% | 1,287 | $7K | |
| 80359 | <1% | 1,287 | $7K | |
| 80353 | <1% | 1,287 | $7K | |
| 80348 | <1% | 1,206 | $6K | |
| 80361 | <1% | 1,205 | $5K | |
| 80365 | <1% | 1,204 | $5K | |
| 80363 | <1% | 1,192 | $5K | |
| 80358 | <1% | 1,191 | $5K | |
| 99442 | <1% | 65 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 54 | $2K |
| 72275 | <1% | 106 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 135 | $1K |
| 20553 | <1% | 28 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 38 | $966.66 |
| 99358 | Prolong nursin fac eval 15m | <1% | 13 | $681.38 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 78 | $325.41 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 327 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 12 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 30 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREYFMAN, LEONID (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Pain Physicians NY PLLC | New York, NY | $809K |
| Island Ambulatory Surgery Center | Brooklyn, NY | $791K |
| BL Pain Management PLLC | Bronx, NY | $416K |
| JSJ Anesthesia and Pain Management PLLC | Brooklyn, NY | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.